ILKAP and cancer: In the context of cancer, ILKAP was described to regulate the susceptibility of ovarian tumor cells to cisplatin, a platinum-based anti-cancer drug (Lorenzato et al., 2016), but never associated with antigen-specific tumor killing by CTLs.